Supplementary material
1.Filippi M, Agosta F, Barkhof F, Dubois B, Fox NC, Frisoni GB et al. EFNS task force: the
use of neuroimaging in the diagnosis of dementia. Eur.J.Neurol. 2012;19:e131-e501.
2.Sorbi S, Hort J, Erkinjuntti T, Fladby T, Gainotti G, Gurvit H et al. EFNS-ENS Guidelines on
the diagnosis and management of disorders associated with dementia. Eur.J.Neurol.
2012;19:1159-79.
3.Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I et al. EFNS guidelines for
the diagnosis and management of Alzheimer's disease. Eur.J.Neurol. 2010;17:1236-48.
4.Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M et al. Recommendations
for the diagnosis and management of Alzheimer's disease and other disorders associated
with dementia: EFNS guideline. Eur.J.Neurol. 2007;14:e1-26.
5.Rossor MN. Dementia and driving: European national guidelines. EFNS Scientist Panel on
Dementia. Eur.J.Neurol. 2000;7:745.
6.Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and
management of Alzheimer's disease and other disorders associated with dementia. The role
of neurologists in Europe. European Federation of Neurological Societies. Eur.J.Neurol.
2000;7:133-44.
7.Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology
1967;17:427-42
8.Fahn S, Elton RL. Members of the Unified Parkinson's Disease Rating Scale Development
Committee. Unified Parkinson's disease rating scale, In: Fahn S, Marsden CD, Calne DB,
Goldstein M, editors. Recent development in Parkinson's disease. Floram Park, New Jersey:
Macmillan Healthcare Information; 1987. p. 153-64. 24.
1
9.Thal DR, Grinberg LT, Attems J. Vascular dementia: different forms of vessel disorders
contribute to the development of dementia in the elderly brain. Exp.Gerontol. 2012;47:81624.
10. Cosentino SA, Jefferson AL, Carey M, Price CC, vis-Garrett K, Swenson R et al. The
clinical diagnosis of vascular dementia: A comparison among four classification systems
and a proposal for a new paradigm. Clin.Neuropsychol. 2004;18:6-21.
11. van der Flier WM, van Straaten EC, Barkhof F, Scheltens P. NINDS AIREN neuroimaging
criteria do not distinguish stroke patients with and without dementia. Neurology
2005;65:1341.
12. Wiederkehr S, Simard M, Fortin C, van RR. Validity of the clinical diagnostic criteria for
vascular dementia: a critical review. Part II. J.Neuropsychiatry Clin.Neurosci. 2008;20:16277.
13. Wiederkehr S, Simard M, Fortin C, van RR. Comparability of the clinical diagnostic criteria
for vascular dementia: a critical review. Part I. J.Neuropsychiatry Clin.Neurosci.
2008;20:150-61
14. Miller BL, Chang L, Mena I, Boone K, Lesser IM. Progressive right frontotemporal
degeneration: clinical, neuropsychological and SPECT characteristics. Dementia
1993;4:204-13.
15. Edwards-Lee T, Miller BL, Benson DF, Cummings JL, Russell GL, Boone K et al. The
temporal variant of frontotemporal dementia. Brain 1997;120 ( Pt 6):1027-40.
16. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar
degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54
2
17. Thompson SA, Patterson K, Hodges JR. Left/right asymmetry of atrophy in semantic
dementia: behavioral-cognitive implications. Neurology 2003;61:1196-203.
18. Mackenzie IR, Baborie A, Pickering-Brown S, Du PD, Jaros E, Perry RH et al.
Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification
and relation to clinical phenotype. Acta Neuropathol. 2006;112:539-49.
19. Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A et al.
Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive
inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies.
Am.J.Pathol. 2006;169:1343-52.
20. Whitwell JL, Jack CR, Jr., Boeve BF, Senjem ML, Baker M, Rademakers R et al. Voxelbased morphometry patterns of atrophy in FTLD with mutations in MAPT or PGRN.
Neurology 2009;72:813-20.
21. Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma.
Ann.Neurol. 2008;64:4-14.
22. Chan D, Anderson V, Pijnenburg Y, Whitwell J, Barnes J, Scahill R et al. The clinical
profile of right temporal lobe atrophy. Brain 2009;132:1287-98.
23. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC et al. Clinical research
criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski
syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
24. Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ et al.
Clinicopathological correlations in corticobasal degeneration. Ann.Neurol. 2011;70:327-40.
3
25. Boeve BF. Links between frontotemporal lobar degeneration, corticobasal degeneration,
progressive supranuclear palsy, and amyotrophic lateral sclerosis. Alzheimer
Dis.Assoc.Disord. 2007;21:S31-S38.
26. Boeve B. Corticobasal degeneration: the syndrome and the disease, In: Litvan I, editor.
Atypical parkinsonian disorders. Humana Totawa: 2005. p. 309-34.
27. Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF et al.
Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006-14.
28. Rohrer JD, Schott JM. Primary progressive aphasia: defining genetic and pathological
subtypes. Curr.Alzheimer Res. 2011;8:266-72.
29. Bonner MF, Ash S, Grossman M. The new classification of primary progressive aphasia
into semantic, logopenic, or nonfluent/agrammatic variants. Curr.Neurol.Neurosci.Rep.
2010;10:484-90.
30. Hof PR, Bouras C, Constantinidis J, Morrison JH. Balint's syndrome in Alzheimer's disease:
specific disruption of the occipito-parietal visual pathway. Brain Res. 1989;493:368-75.
31. Tang-Wai DF, Graff-Radford NR, Boeve BF, Dickson DW, Parisi JE, Crook R et al.
Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy.
Neurology 2004;63:1168-74.
32. Colby DW, Prusiner SB. Prions. Cold Spring Harb.Perspect.Biol. 2011;3:a006833.
33. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion
diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11:618-28.
34. Federico A, Di D, I, Bianchi S, Di PC, Taglia I, Dotti MT. Hereditary cerebral small vessel
diseases: a review. J.Neurol.Sci. 2012;322:25-30.
4
35. Yamada K, Sakai K, Akazawa K, Sugimoto N, Nakagawa M, Mizuno T. Detection of early
neuronal damage in CADASIL patients by q-space MR imaging. Neuroradiology 2012.
36. Pescini F, Nannucci S, Bertaccini B, Salvadori E, Bianchi S, Ragno M et al. The Cerebral
Autosomal-Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy
(CADASIL) Scale: a screening tool to select patients for NOTCH3 gene analysis. Stroke
2012;43:2871-76.
37. Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L et al. Differentiation of
frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT.
J.Neurol.Neurosurg.Psychiatry 2012;83:1063-70.
38. Jack CR, Jr., Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D et al. The
Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J.Magn
Reson.Imaging 2008;27:685-91.
39. Zhang Y, Minoshima S, Vesselle H, Lewis DH. A case of Creutzfeldt-Jakob disease
mimicking corticobasal degeneration: FDG PET, SPECT, and MRI findings.
Clin.Nucl.Med. 2012;37:e173-e175.
40. Caselli RJ, Jack CR, Jr., Petersen RC, Wahner HW, Yanagihara T. Asymmetric cortical
degenerative syndromes: clinical and radiologic correlations. Neurology 1992;42:1462-68.
41. Mazere J, Meissner WG, Mayo W, Sibon I, Lamare F, Guilloteau D et al. Progressive
supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine
transporter with [123I]-iodobenzovesamicol. Radiology 2012;265:537-43.
42. Kurata T, Kametaka S, Ohta Y, Morimoto N, Deguchi S, Deguchi K et al. PSP as
distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early
stage. Intern.Med. 2011;50:2775-81.
5
43. Ciccocioppo F, Lanuti P, Marchisio M, Gambi F, Santavenere E, Pierdomenico L et al.
Expression and phosphorylation of protein kinase C isoforms in Abeta(1-42) activated T
lymphocytes from Alzheimers disease. Int.J.Immunopathol.Pharmacol. 2008;21:23-33.
44. Miscia S, Ciccocioppo F, Lanuti P, Velluto L, Bascelli A, Pierdomenico L et al. Abeta(142) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease.
Neurobiol.Aging 2009;30:394-406.
45. Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di NM et al. Peripheral cytokines
profile in Parkinson's disease. Brain Behav.Immun. 2009;23:55-63.
46. Dong Y, Sharma VK, Chan BP, Venketasubramanian N, Teoh HL, Seet RC et al. The
Montreal Cognitive Assessment (MoCA) is superior to the Mini-Mental State Examination
(MMSE) for the detection of vascular cognitive impairment after acute stroke. J.Neurol.Sci.
2010;299:15-18.
47. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
Sleep 1991;14:540-45.
6